INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort
INmune Bio Inc. - Common stock (INMB)
Company Research
Source: GlobeNewswire
BOCA RATON, Fla., Sept. 26, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, continues to advance its Natural Killer (NK) cell therapy, INKmune™, in a Phase I/II trial (the “CaRe PC” trial) for men with metastatic Castration-Resistant Prostate Cancer (mCRPC). The Company is pleased to announce initial results from the first patient cohort in the trial. Mark Lowdell, CSO and inventor of INKmune™, said, “The enrollment of the first cohort ran entirely in-line with our predicted timelines and confirmed the excellent safety profile with all patients receiving treatment as out-patient without the need for pre-medication of any kind. Furthermore, even at this lowest dose of INKmune™, there is clear evidence of persistent immunologic effects of INKmune™ treatment in these men with mCRPC. Blinded analysis of the monitoring blood samples from the first three patients showed changes in the phen
Show less
Read more
Impact Snapshot
Event Time:
INMB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INMB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INMB alerts
High impacting INmune Bio Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
INMB
News
- INmune Bio, Inc. (NASDAQ: INMB) is now covered by analysts at Raymond James. They set an "outperform" rating and a $18.00 price target on the stock.MarketBeat
- INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB EndpointsGlobeNewswire
- INmune Bio Announces $13.0 Million Registered Direct OfferingGlobeNewswire
- INmune Bio, Inc.'s (NASDAQ:INMB) top owners are individual investors with 44% stake, while 23% is held by institutions [Yahoo! Finance]Yahoo! Finance
- INmune Bio Inc. to Present at the Baird 2024 Global Healthcare ConferenceGlobeNewswire
INMB
Sec Filings
- 9/26/24 - Form 8-K
- 9/17/24 - Form 8-K
- 9/16/24 - Form 4
- INMB's page on the SEC website